MediciNovaMNOV +1.15%32 PS Ratio is 101.92 as of Jul. 01, 2026, which is 0% above its 10-year median of 101.54. GuruFocus rates MNOV with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 934 Biotechnology companies, MediciNova ranks worse than 84.9% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MediciNova's share price is $1.325.
MediciNova's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, MediciNova's PS Ratio for today is 101.92.
Good Sign:
MediciNova Inc stock PS Ratio (=101.92) is close to 1-year low of 94.62.
The historical rank and industry rank for MediciNova's PS Ratio or its related term are showing as below:
MNOV'
s PS Ratio Range Over the Past 10 Years
Min: 26.12 Med: 101.54 Max: 3060
Current: 101.92
During the past 13 years, MediciNova's highest PS Ratio was 3060.00. The lowest was 26.12. And the median was 101.54.
MNOV's PS Ratio is ranked worse than 84.9% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs MNOV: 101.92
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
MediciNova PS Ratio Related Terms
MediciNova PS Ratio Historical Data
* Premium members only.
The historical data trend for MediciNova's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MediciNova's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediciNova PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediciNova's PS Ratio distribution charts can be found below:
* The bar in red indicates where MediciNova's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
MediciNova's Share Price of today is $1.325. MediciNova's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
MediciNova (MNOV) has a PS Ratio of 101.92 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MediciNova and its competitors. This is near median its historical median of 101.54. Over the past decade, MediciNova's PS Ratio has ranged from 26.12 to 3,060.00. According to the industry distribution chart, MediciNova ranks #793 out of 934 companies in the Biotechnology industry, placing it in the top 84.9%.
Is MediciNova's PS Ratio too high?
MediciNova's current PS Ratio of 101.92 is near median its 10-year median of 101.54. Over the past 10 years, this metric has ranged from a low of 26.12 to a high of 3,060.00. The Biotechnology industry median PS Ratio is 9.52. MediciNova's value of 101.92 is 971.2% above this industry median. Based on the distribution chart, MediciNova ranks #793 out of 934 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MediciNova has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's PS Ratio compare to TCRX and PMVP?
According to the Biotechnology industry distribution chart, MediciNova ranks #793 out of 934 companies for PS Ratio. This places MediciNova in the lower half of its industry. The industry median PS Ratio is 9.52. MediciNova's value of 101.92 is 971.2% above this benchmark. Historically, MediciNova's own PS Ratio has ranged from 26.12 to 3,060.00 over the past decade. While the company's 10-year median is 101.54 vs. the industry median of 9.52, MediciNova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediciNova's current PS Ratio of 101.92 is 971.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MediciNova and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediciNova's current PS Ratio is 101.92, which is near median its own 10-year median of 101.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current PS Ratio of 101.92. The current PS Ratio is 101.92, which is near median its 10-year median of 101.54 and 971.2% above the Biotechnology industry median of 9.52. MediciNova's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For MediciNova (MNOV), the current PS Ratio is 101.92 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
32GF Score
Get the complete analysis for MNOV
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNOV has been successfully added to your 
